Editorial comment on: low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in …
C Maier - European urology, 2007 - pubmed.ncbi.nlm.nih.gov
Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention
trials using 5-alpha-reductase inhibitors … Prostatic Neoplasms / drug therapy Prostatic
Neoplasms / enzymology …
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention
trials using 5-alpha-reductase inhibitors … Prostatic Neoplasms / drug therapy Prostatic
Neoplasms / enzymology …
Editorial comment on: low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in …
T Prayer-Galetti - European urology, 2007 - pubmed.ncbi.nlm.nih.gov
Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials
using 5-alpha-reductase inhibitors Editorial comment on: Low-activity V89L variant in SRD5A2
is associated with aggressive prostate cancer risk: an explanation for the adverse effects
observed in chemoprevention trials using 5-alpha-reductase inhibitors … Prostatic Neoplasms …
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials
using 5-alpha-reductase inhibitors Editorial comment on: Low-activity V89L variant in SRD5A2
is associated with aggressive prostate cancer risk: an explanation for the adverse effects
observed in chemoprevention trials using 5-alpha-reductase inhibitors … Prostatic Neoplasms …
以上显示的是最相近的搜索结果。 查看全部搜索结果